AI assistant
PCAS — Earnings Release 2016
Apr 20, 2016
1590_iss_2016-04-20_e9ebade1-3e07-4f68-b851-a00abf6ef110.pdf
Earnings Release
Open in viewerOpens in your device viewer
SHARP GROWTH IN NET SALES AGAIN
Longjumeau, April 20, 2016
PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its consolidated net sales for the 1st quarter of 2016.
The PCAS Group's consolidated net sales totaled €45.3 million in the 1st quarter of 2016, up by 12.2 % compared to the same period in the previous financial year (+10.2 % at constant exchange rate).
| in millions of euros | 2016 | 2015 | % change | 2016 At a constant exchange rate |
% change |
|---|---|---|---|---|---|
| Net sales at 31 march | 45.3 | 40.4 | 12.2 % | 44.5 | 10.2 % |
| Pharmaceutical Synthesis | 30.2 | 25.7 | 17.5 % | 29.5 | 14.6 % |
| Fine specialty chemicals | 15.1 | 14.6 | 2.9 % | 15.0 | 2.4 % |
Pharmaceutical Synthesis
Pharmaceutical synthesis activities in Health generated €30.2 million, up 17.5 % compared to 2015 (+14.6 % at constant exchange rate), particularly sustained by the Exclusive activity.
Fine specialty chemicals
Net sales of Fine Specialty Chemicals amounted to €15.1 million, up 2.9 % compared to 2015 (+2.4 % at a constant exchange rate), this activity growing both in Performance Additives and Advanced Specialty Chemicals.
Outlook for the current year
The company thus confirms its sales growth targets for 2016 as a whole, excluding growth through acquisition, both in Pharmaceutical Synthesis and in Fine Specialty Chemicals.
About PCAS
PCAS specialises in the development and production of complex molecules for Life Sciences and Innovative Technologies. With 7% of its turnover dedicated to R&D and a wide international presence, PCAS is the preferred industrial partner of market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments, and also includes two subsidiaries with very strong potential: Protéus in biotechnology and Enersens in high-performance insulation. With a particularly high standard of performance, PCAS achieved net sales of €179.1 million in 2015 and employs nearly 900 people in six countries. For more information about PCAS: www.pcas.com
Vincent Touraille / Eric Moissenot PCAS
PCAS NewCap
Emmanuel Huynh / Louis-Victor Delouvrier NewCap Financial Communication & investors relations
Tel. : +33 1 69 79 61 32 www.pcas.com
Tel. : +33 1 44 71 98 53 [email protected]